QIBA弥散加权MRI概要:表观弥散系数作为定量影像生物标志物
本文介绍定量影像生物标志物联盟(QIBA)弥散加权影像生物标志物委员会将表观弥散系数(ADC)概要推进至脑、肝、前列腺和乳腺的临床可行阶段,并基于近期文献提出平均病灶ADC变化的计量学基准:脑病灶变化超过8%、肝病灶超过27%、前列腺病灶超过27%、乳腺病灶超过15%可声称代表真实变化(95%置信度)。报告还讨论了ADC概要的开发历程及标准化实施工作流程。
要点
- 脑病灶平均ADC变化超过8%可声称代表真实变化(95%置信度)。
- 肝及前列腺病灶平均ADC变化超过27%可声称代表真实变化(95%置信度)。
- 乳腺病灶平均ADC变化超过15%可声称代表真实变化(95%置信度)。
核心结论
- QIBA ADC概要指南应能实现ADC作为定量影像生物标志物的成功临床应用,并确保可重复的ADC测量,从而可靠评估纵向变化和治疗反应。
研究设计与样本
- 本文为QIBA弥散加权影像生物标志物委员会的报告,基于多项ADC重复性研究提炼概要,并利用近期文献提出计量学基准更新。
- ADC概要已从共识阶段推进至脑、肝、前列腺和乳腺的临床可行阶段。
诊断标准与关键数值
- 脑病灶平均ADC变化超过8%可声称代表真实变化(95%置信度)。
- 肝病灶平均ADC变化超过27%可声称代表真实变化(95%置信度)。
- 前列腺病灶平均ADC变化超过27%可声称代表真实变化(95%置信度)。
- 乳腺病灶平均ADC变化超过15%可声称代表真实变化(95%置信度)。
临床应用与阅片要点
- ADC概要描述了在可接受置信限内达到所述性能声明的详细程序,以实现先进定量弥散加权MRI在临床中的标准化实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The apparent diffusion coefficient (ADC) provides a quantitative measure of water mobility that can be used to probe alterations in tissue microstructure due to disease or treatment. Establishment of the accepted level of variance in ADC measurements for each clinical application is critical for its successful implementation. The Diffusion-Weighted Imaging Biomarker Committee of the Quantitative Imaging Biomarkers Alliance (QIBA) has recently advanced the ADC Profile from the consensus to clinically feasible stage for the brain, liver, prostate, and breast. This profile distills multiple studies on ADC repeatability and describes detailed procedures to achieve stated performance claims on an observed ADC change within acceptable confidence limits. In addition to reviewing the current ADC Profile claims, this report has used recent literature to develop proposed updates for establishing metrology benchmarks for mean lesion ADC change that account for measurement variance. Specifically, changes in mean ADC exceeding 8% for brain lesions, 27% for liver lesions, 27% for prostate lesions, and 15% for breast lesions are claimed to represent true changes with 95% confidence. This report also discusses the development of the ADC Profile, highlighting its various stages, and describes the workflow essential to achieving a standardized implementation of advanced quantitative diffusion-weighted MRI in the clinic. The presented QIBA ADC Profile guidelines should enable successful clinical application of ADC as a quantitative imaging biomarker and ensure reproducible ADC measurements that can be used to confidently evaluate longitudinal changes and treatment response for individual patients.
引用
- Boss MA, Malyarenko D, Partridge S, et al. The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker. Radiology. 2024. PMID: 39377680. doi:10.1148/radiol.233055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。